Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02963259 · ClinicalTrials.gov registry record
IPG Replacement Study (PREFERENCE-H)
A clinical trial, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 17
- Enrollment target
NCT02963259: Completed study, sponsored by Abbott Medical Devices.
NCT02963259 is a clinical trial that has completed, run by Abbott Medical Devices. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02963259 has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 17 participants
- Enrollment target
Study Summary
This post-marketing evaluation has been designed to consistently investigate the subject's preference when switching from a Medtronic® constant voltage or constant current device to a St Jude Medical Infinity™ or St Jude Medical Brio™ constant current system. As electrodes will not be re-positioned, differences in subject's preference are to be explained by the difference in shape of the delivered pulse or waveform between the two systems.
Primary Outcome
Proportion of subjects who preferred constant current device over constant voltage, tested against a performance goal (PG) of 50.0% at the 3-month follow-up visit.
Interventions
- DEVICE SJM Infinity™ DBS IPG or SJM Brio™ DBS IPG system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-03-29 |
| Est. Completion | 2020-01-31 |
What the finished NCT02963259 record still lists
NCT02963259 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 17 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which SJM Infinity™ DBS IPG or SJM Brio™ DBS IPG system is the first listed.
NCT02963259 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02963259 about?
NCT02963259 is a clinical study titled "IPG Replacement Study (PREFERENCE-H)". This post-marketing evaluation has been designed to consistently investigate the subject's preference when switching from a Medtronic® constant voltage or constant current device to a St Jude Medical Infinity™ or St Jude Medical Brio™ constant current system. As electrodes will not be re-positioned,...
What is the current status of trial NCT02963259?
This trial is currently completed. The enrollment target is 17 participants. The study started on 2017-03-29. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT02963259?
The interventions under investigation include: SJM Infinity™ DBS IPG or SJM Brio™ DBS IPG system (DEVICE).
Who is sponsoring clinical trial NCT02963259?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI